Journal: Physiological Reports

Article Title: Short‐term semaglutide treatment improves FGF21 responsiveness in primary hepatocytes isolated from high fat diet challenged mice

doi: 10.14814/phy2.15620

Figure Lengend Snippet: Antibodies utilized in the current study.

Article Snippet: Recombinant human FGF21 (hFGF21) was purchased from Cayman Chemical.

Techniques:

Journal: Physiological Reports

Article Title: Short‐term semaglutide treatment improves FGF21 responsiveness in primary hepatocytes isolated from high fat diet challenged mice

doi: 10.14814/phy2.15620

Figure Lengend Snippet: Short‐term semaglutide treatment improves glucose tolerance and reduces body weight in HFD‐challenged mice. (a) Diagram shows the animal experimental design. (b) Body weight changes during last 7 days in the three indicated groups. (c) Blood glucose level and area under the curve (AUC) during IPGTT. (d) Fasting (overnight) blood glucose levels at the end of the experiment for indicated groups. (e–g) Fasting plasma leptin (e), adiponectin (f), and FGF21 (g) levels. (h–m) Fat pad weights including epididymal (h, eWAT) and inguinal (i, iWAT) white adipose tissue and brown adipose tissue (j, BAT). (k) eWAT weight to body weight ratio. (l) iWAT weight to body weight ratio. (m) BAT weight to body weight ratio. Sema, semaglutide. Data are shown as the mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: Recombinant human FGF21 (hFGF21) was purchased from Cayman Chemical.

Techniques: Clinical Proteomics

Journal: Physiological Reports

Article Title: Short‐term semaglutide treatment improves FGF21 responsiveness in primary hepatocytes isolated from high fat diet challenged mice

doi: 10.14814/phy2.15620

Figure Lengend Snippet: Seven‐day semaglutide treatment restores HFD‐induced attenuation on ERK phosphorylation to hFGF21 treatment in hepatocytes. (a) Western blotting show expression levels of indicated protein in MPH isolated from LFD‐fed mice after 1 h hFGF21 treatment with indicated dose. (b, c) Densitometric analyses for pERK (p44, Thr202) and pERK (p42, Tyr204) with indicated treatment. (d) Western blotting show expression levels of indicated protein in MPH isolated from HFD‐fed mice after 1 h hFGF21 treatment with indicated dose. (e, f) Densitometric analyses for pERK (p44, Thr202) and pERK (p42, Tyr204) with indicated treatment. (g) Western blotting show expression levels of indicated protein in MPH isolated from semaglutide‐treated mice after 1 h hFGF21 treatment with indicated dose. (h, i) Densitometric analyses for pERK (p44, Thr202) and pERK (p42, Tyr204) with indicated treatment. Data are shown as the mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: Recombinant human FGF21 (hFGF21) was purchased from Cayman Chemical.

Techniques: Phospho-proteomics, Western Blot, Expressing, Isolation

Journal: Physiological Reports

Article Title: Short‐term semaglutide treatment improves FGF21 responsiveness in primary hepatocytes isolated from high fat diet challenged mice

doi: 10.14814/phy2.15620

Figure Lengend Snippet: Seven‐day semaglutide treatment restores the stimulatory effects of hFGF21 on its downstream target gene expressions in MPH. (a) qRT‐PCR show effect of indicated dose of hFGF21 treatment (4 h) on expression of cFos in MPH isolated from LFD‐fed, HFD‐fed, and semaglutide‐treated mice. (b) qRT‐PCR show effect of indicated dose of hFGF21 treatment (4 h) on expression of Egr1 in MPH isolated from LFD‐fed, HFD‐fed, and semaglutide‐treated mice. Data are shown as the mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: Recombinant human FGF21 (hFGF21) was purchased from Cayman Chemical.

Techniques: Quantitative RT-PCR, Expressing, Isolation

Journal: Physiological Reports

Article Title: Short‐term semaglutide treatment improves FGF21 responsiveness in primary hepatocytes isolated from high fat diet challenged mice

doi: 10.14814/phy2.15620

Figure Lengend Snippet: Seven‐day semaglutide treatment improves FGF21 sensitivity and attenuates the effect of HFD feeding on hepatic gene expression. (a) Western blotting show expression levels of FGF21 in the liver of three indicated groups. (b–d) qRT‐PCR shows the comparison of expression levels on Fgf21 (b) and genes that encode its receptor, Fgfr1 (c) and co‐receptor Klb (d) in the liver of three indicated groups. (e) qRT‐PCR shows the comparison of expression levels of lipogenic and fatty acid oxidation genes in the liver of three indicated groups. Data are shown as the mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: Recombinant human FGF21 (hFGF21) was purchased from Cayman Chemical.

Techniques: Gene Expression, Western Blot, Expressing, Quantitative RT-PCR, Comparison

Journal: Physiological Reports

Article Title: Short‐term semaglutide treatment improves FGF21 responsiveness in primary hepatocytes isolated from high fat diet challenged mice

doi: 10.14814/phy2.15620

Figure Lengend Snippet: Seven‐day semaglutide treatment recovers HFD‐induced alteration in a battery of adipose‐specific genes. (a–c) qRT‐PCR shows the comparison of expression levels on Fgfr1 (a), Klb (b) and Fgf21 (c) in the eWAT of three indicated groups. (d) qRT‐PCR shows the comparison of expression levels of a battery of adipose tissue‐specific genes in the eWAT of three indicated groups. (e) The diagram shows the observed effects of short term semaglutide treatment on mice fed with HFD. In MPH, seven‐day semaglutide treatment restores the response to hFGF21 treatment. In the liver and eWAT, the treatment improves FGF21 sensitivity and restores HFD‐induced attenuation on genes that involved in maintaining lipid homeostasis and other adipose tissue‐specific genes. Data are shown as the mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: Recombinant human FGF21 (hFGF21) was purchased from Cayman Chemical.

Techniques: Battery, Quantitative RT-PCR, Comparison, Expressing